These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27836670)

  • 1. In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.
    Sager JE; Tripathy S; Price LS; Nath A; Chang J; Stephenson-Famy A; Isoherranen N
    Biochem Pharmacol; 2017 Jan; 123():85-96. PubMed ID: 27836670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo.
    Gufford BT; Lu JB; Metzger IF; Jones DR; Desta Z
    Drug Metab Dispos; 2016 Apr; 44(4):544-53. PubMed ID: 26802129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective Metabolism of Bupropion to Active Metabolites in Cellular Fractions of Human Liver and Intestine.
    Bamfo NO; Lu JB; Desta Z
    Drug Metab Dispos; 2023 Jan; 51(1):54-66. PubMed ID: 35512805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
    Reese MJ; Wurm RM; Muir KT; Generaux GT; St John-Williams L; McConn DJ
    Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.
    Xue C; Zhang X; Cai W
    Pharmaceutics; 2017 Dec; 10(1):. PubMed ID: 29267251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro.
    Sager JE; Price LS; Isoherranen N
    Drug Metab Dispos; 2016 Oct; 44(10):1709-19. PubMed ID: 27495292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.
    Masters AR; Gufford BT; Lu JB; Metzger IF; Jones DR; Desta Z
    J Pharmacol Exp Ther; 2016 Aug; 358(2):230-8. PubMed ID: 27255113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion.
    Dash RP; Rais R; Srinivas NR
    Xenobiotica; 2018 Sep; 48(9):945-957. PubMed ID: 28876959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition.
    VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2012 Jan; 40(1):47-53. PubMed ID: 21976621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of CYP2D6 activity by bupropion.
    Kotlyar M; Brauer LH; Tracy TS; Hatsukami DK; Harris J; Bronars CA; Adson DE
    J Clin Psychopharmacol; 2005 Jun; 25(3):226-9. PubMed ID: 15876900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction.
    He J; Yu Y; Prasad B; Chen X; Unadkat JD
    Biopharm Drug Dispos; 2014 Jul; 35(5):253-63. PubMed ID: 24436229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion.
    Güzey C; Norström A; Spigset O
    Ther Drug Monit; 2002 Jun; 24(3):436-7. PubMed ID: 12021638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS.
    Masters AR; McCoy M; Jones DR; Desta Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():201-208. PubMed ID: 26946423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enantioselective metabolism of primaquine by human CYP2D6.
    Fasinu PS; Tekwani BL; Nanayakkara NP; Avula B; Herath HM; Wang YH; Adelli VR; Elsohly MA; Khan SI; Khan IA; Pybus BS; Marcsisin SR; Reichard GA; McChesney JD; Walker LA
    Malar J; 2014 Dec; 13():507. PubMed ID: 25518709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.
    Steuer AE; Schmidhauser C; Tingelhoff EH; Schmid Y; Rickli A; Kraemer T; Liechti ME
    PLoS One; 2016; 11(3):e0150955. PubMed ID: 26967321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
    Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
    Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates.
    Liu LY; Han YL; Zhu JH; Yu Q; Yang QJ; Lu J; Guo C
    Biomed Chromatogr; 2015 Mar; 29(3):437-44. PubMed ID: 25098274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum to "In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation" [Biochem. Pharmacol. 123(2017)85-96].
    Sager JE; Tripathy S; Price LSL; Nath A; Chang J; Stephenson-Famy A; Isoherranen N
    Biochem Pharmacol; 2021 Jan; 183():114306. PubMed ID: 33161206
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude.
    Venkatakrishnan K; Obach RS
    Drug Metab Dispos; 2005 Jun; 33(6):845-52. PubMed ID: 15788540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.